<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37804660</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>124</Volume><Issue>Pt B</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>Low-dose naltrexone use for the management of post-acute sequelae of COVID-19.</ArticleTitle><Pagination><StartPage>110966</StartPage><MedlinePgn>110966</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2023.110966</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(23)01291-2</ELocationID><Abstract><AbstractText>The global prevalence of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) stands at approximately 43&#xa0;% among individuals who have previously had acute COVID-19. In contrast, in the United States, the National Center for Health Statistics (NCHS) estimates that around 11&#xa0;% of individuals who have been infected with SARS-CoV-2 go on to experience long COVID. The underlying causes of PASC remains under investigation, and there are no currently established FDA-approved therapies. One of the leading hypotheses for the cause of PASC is the persistent activation of innate immune cells with increase systemic inflammation. Naltrexone is a medication with anti-inflammatory and immunomodulatory properties that has been used in other conditions that overlap with PASC. We performed a retrospective review of a clinical cohort of 59 patients at a single academic center who received low-dose naltrexone (LDN) off-label as a potential therapeutic intervention for PASC. The use of LDN was associated with a fewer number of symptoms, improved clinical symptoms (fatigue, post-exertional malaise, unrefreshing sleep, and abnormal sleep pattern), and a better functional status. This observation warrants testing in rigorous, randomized, placebo-controlled clinical trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonilla</LastName><ForeName>Hector</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases &amp; Geographic Medicine, L-134 Stanford University, 300 Pasteur Dr., Palo Alto, CA 94305, United States. Electronic address: Hbonilla@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department: Biomedical Data Science, Stanford University, Professor X347 MSOB, Palo Alto, CA 94305, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marconi</LastName><ForeName>Vincent C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, United States; Hubert Department of Global Health, Rollins School of Public Health, Atlanta, GA, United States; Atlanta Veterans Affairs Health Care System, Decatur, GA, United States; Health Sciences Research Building, 1760 Haygood Dr NE, Room W325, Atlanta, GA 30322, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafer</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases &amp; Geographic Medicine, Stanford University, 3652 Biomedical Innovations Building, 3rd Floor, Palo Alto, CA 94305, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McComsey</LastName><ForeName>Grace A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Medicine, Case Western Reserve University and University Hospitals of Cleveland, 11100 Euclid Ave., Cleveland, OH 44106, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miglis</LastName><ForeName>Mitchel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford University, 213 Quarry Road, Palo Alto, CA 94304, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department: Medicine - Med/Cardiovascular Medicine, Stanford University, 300 Pasteur Dr # H2157, Palo Alto, CA 94305-2200, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonilla</LastName><ForeName>Andres</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular, Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eggert</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, 300 Pasteur Dr Rm H3143 MC 5236, Palo Alto, CA 94305-2200, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Linda N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Medicine - Primary Care and Population Health, Stanford University, 211 Quarry Rd Ste 205 MC 5987, Palo Alto, CA 94304, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AI050409</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002548</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 TR004528</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5S6W795CQM</RegistryNumber><NameOfSubstance UI="D009271">Naltrexone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009271" MajorTopicYN="N">Naltrexone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LDN</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Long haulers</Keyword><Keyword MajorTopicYN="N">Naltrexone</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae of COVID-19</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: V.C.M. has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences, and ViiV. GM has received research funding from Genentech, Roche, Merck, Pfizer, Redhill, Cognivue, and consultations fees (all unrelated to this work) from Merck, Janssen, Gilead, Theratechnologies, and ViiV. LG has received research funding from Pfizer and advisory fees from United Healthcare. HB has received research funding from Pfizer and advisory fees from United Healthcare. LE reports serving on the advisory boards for AstraZeneca and Regeneron. All other authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>2</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>8</Day><Hour>2</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>7</Day><Hour>18</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37804660</ArticleId><ArticleId IdType="mid">NIHMS1983918</ArticleId><ArticleId IdType="pmc">PMC11028858</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2023.110966</ArticleId><ArticleId IdType="pii">S1567-5769(23)01291-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>NIH. COVID-19 Treatment Guidelines. April, 20
2023; https://www.covid19treatmentguidelines.nih.gov/</Citation></Reference><Reference><Citation>NIH. RECOVER: Researching COVID to Enhance Recovery. April, 23
2023; https://recovercovid.org</Citation></Reference><Reference><Citation>Couzin-Frankel J Clues to long COVID. Science. Jun 17 2022;376(6599):1261&#x2013;1265. doi:10.1126/science.add4297</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.add4297</ArticleId><ArticleId IdType="pubmed">35709281</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. Nat Med. May 2022;28(5):911&#x2013;923. doi:10.1038/s41591-022-01810-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruun KD, Amris K, Vaegter HB, et al. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial. Trials. Nov 15 2021;22(1):804. doi:10.1186/s13063-021-05776-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-021-05776-7</ArticleId><ArticleId IdType="pmc">PMC8591911</ArticleId><ArticleId IdType="pubmed">34781989</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo OPP, Tuominena E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue: Biomedicine, Health &amp; Behavoir. December 23th 2019;doi:10.1080/21641846.2019.1692770</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2019.1692770</ArticleId></ArticleIdList></Reference><Reference><Citation>Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. Feb 2013;65(2):529&#x2013;38. doi:10.1002/art.37734</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37734</ArticleId><ArticleId IdType="pubmed">23359310</ArticleId></ArticleIdList></Reference><Reference><Citation>Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization. Med Sci (Basel). Sep 21 2018;6(4)doi:10.3390/medsci6040082</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci6040082</ArticleId><ArticleId IdType="pmc">PMC6313374</ArticleId><ArticleId IdType="pubmed">30248938</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. Apr 16 2022;doi:10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonilla HQT, Tiwari A, Bonilla AE, Miglis M, Yang P, Eggert L, Sharifi H, Horomanski A, Subramanian A, Smirnoff L, Simpson N, Halawi H, Sum-Ping O, Kalinowski A, Patel Z, Shafer R, Geng L. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic. Front Neurol. 2023; 14:1090747. doi: 10.3389/fneur.2023</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2023</ArticleId><ArticleId IdType="pmc">PMC9998690</ArticleId><ArticleId IdType="pubmed">36908615</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Boon G, Barco S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. Jul 2020;56(1)doi:10.1183/13993003.01494-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01494-2020</ArticleId><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. National Center for Health Statistics. Nearly One in Five American Adults Who Have Had COVID-19 Still Have &#x201c;Long COVID&#x201d;. 2022;</Citation></Reference><Reference><Citation>Ford ND, Slaughter D, Edwards D, et al. Long COVID and Significant Activity Limitation Among Adults, by Age - United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. MMWR Morb Mortal Wkly Rep. Aug 11 2023;72(32):866&#x2013;870. doi:10.15585/mmwr.mm7232a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7232a3</ArticleId><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. Apr 2022;43(4):268&#x2013;270. doi:10.1016/j.it.2022.02.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenstein TK. The Role of Opioid Receptors in Immune System Function. Front Immunol. 2019;10:2904. doi:10.3389/fimmu.2019.02904</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02904</ArticleId><ArticleId IdType="pmc">PMC6934131</ArticleId><ArticleId IdType="pubmed">31921165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaveriaux-Ruff C, Matthes HW, Peluso J, Kieffer BL. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci U S A. May 26 1998;95(11):6326&#x2013;30. doi:10.1073/pnas.95.11.6326</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6326</ArticleId><ArticleId IdType="pmc">PMC27678</ArticleId><ArticleId IdType="pubmed">9600964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Tian Z, Wei H. Developmental and Functional Control of Natural Killer Cells by Cytokines. Front Immunol. 2017;8:930. doi:10.3389/fimmu.2017.00930</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00930</ArticleId><ArticleId IdType="pmc">PMC5543290</ArticleId><ArticleId IdType="pubmed">28824650</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, McLaughlin PJ, Zagon IS. Ontogeny of the opioid growth factor, [Met5]-enkephalin, preproenkephalin gene expression, and the zeta opioid receptor in the developing and adult aorta of rat. Dev Dyn. Apr 1998;211(4):327&#x2013;37. doi:10.1002/(SICI)1097-0177(199804)211:4&lt;327::AID-AJA4&gt;3.0.CO;2-J</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0177(199804)211:4&lt;327::AID-AJA4&gt;3.0.CO;2-J</ArticleId><ArticleId IdType="pubmed">9566952</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchi S, Moretti S, Castelli M, et al. Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages. Brain Behav Immun. Mar 2012;26(3):480&#x2013;8. doi:10.1016/j.bbi.2011.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2011.12.010</ArticleId><ArticleId IdType="pubmed">22240038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucic N, Racki V, Sverko R, Vidovic T, Grahovac I, Mrsic-Pelcic J. Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells. Int J Mol Sci. Aug 5 2021;22(16)doi:10.3390/ijms22168429</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168429</ArticleId><ArticleId IdType="pmc">PMC8395119</ArticleId><ArticleId IdType="pubmed">34445130</ArticleId></ArticleIdList></Reference><Reference><Citation>Selfridge BR, Wang X, Zhang Y, et al. Structure-Activity Relationships of (+)-Naltrexone-Inspired Toll-like Receptor 4 (TLR4) Antagonists. J Med Chem. Jun 25 2015;58(12):5038&#x2013;52. doi:10.1021/acs.jmedchem.5b00426</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b00426</ArticleId><ArticleId IdType="pmc">PMC4634939</ArticleId><ArticleId IdType="pubmed">26010811</ArticleId></ArticleIdList></Reference><Reference><Citation>Cant R, Dalgleish AG, Allen RL. Naltrexone Inhibits IL-6 and TNFalpha Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors. Front Immunol. 2017;8:809. doi:10.3389/fimmu.2017.00809</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00809</ArticleId><ArticleId IdType="pmc">PMC5504148</ArticleId><ArticleId IdType="pubmed">28744288</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H, Muraki K, Staines D, Marshall-Gradisnik S. Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. Front Immunol. 2019;10:2545. doi:10.3389/fimmu.2019.02545</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02545</ArticleId><ArticleId IdType="pmc">PMC6834647</ArticleId><ArticleId IdType="pubmed">31736966</ArticleId></ArticleIdList></Reference><Reference><Citation>Skolnick P, Davis H, Arnelle D, Deaver D. Translational potential of naloxone and naltrexone as TLR4 antagonists. Trends Pharmacol Sci. Sep 2014;35(9):431&#x2013;2. doi:10.1016/j.tips.2014.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2014.06.008</ArticleId><ArticleId IdType="pubmed">25109569</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kelly B, Vidal L, McHugh T, Woo J, Avramovic G, Lambert JS. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav Immun Health. Oct 2022;24:100485. doi:10.1016/j.bbih.2022.100485</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicine Io. Recommendations. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. 2015. The National Academies Collection: Reports funded by National Institutes of Health.</Citation></Reference><Reference><Citation>Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP, Natelson BH. Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post-Coronavirus Disease. JACC Heart Fail. Dec 2021;9(12):927&#x2013;937. doi:10.1016/j.jchf.2021.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2021.10.002</ArticleId><ArticleId IdType="pmc">PMC8629098</ArticleId><ArticleId IdType="pubmed">34857177</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C, Freitag H, Meyer-Arndt L, et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. Aug 30 2022;13(1):5104. doi:10.1038/s41467-022-32507-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32507-6</ArticleId><ArticleId IdType="pmc">PMC9426365</ArticleId><ArticleId IdType="pubmed">36042189</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozgain I, Pozgain Z, Degmecic D. Placebo and nocebo effect: a mini-review. Psychiatr Danub. Jun 2014;26(2):100&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24909245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L
Low-dose Naltrexone for Post-COVID Fatigue Syndrome. University of British Columbia. https://clinicaltrials.gov/ct2/show/NCT05430152.
2022;</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>